News • Tropical parasite

Treating leishmaniasis with natural compound 2HF

Current treatment options for the parasitic disease leishmaniasis are largely ineffective, expensive, and tend to be plagued by resistant parasites and side effects. Now, researchers reporting in PLOS Neglected Tropical Diseases have showed that a natural flavonoid is effective at treating Leishmania amazonensis infections.

Leishmaniasis is endemic to 98 countries and affects more than 12 million people around the world. Treatment is possible with pentavalent antimonial, but many Leishmania parasites have become resistant to antimonial chemotherapy. Flavonoids— a group of natural compounds that are isolated from fruits, vegetables, wine and coffee— have been considered a promising candidate for leishmanisis treatment. 2’-Hydroxyflavanone (2HF), part of a class of flavonoids found in citrus fruits, is already being studied for its use in cancer chemotherapy.

Photo
Illustrative photos of 2HF and meglumine antimoniate against L. amazonensis-infected macrophages
Source: Almeida-Amaral, et al (CC BY 4.0, 2018)

In the new work, Elmo Almeida-Amaral, of the Oswaldo Cruz Foundation, Brazil, and colleagues studied the effect of 2HF on wild-type and antimony-resistant L. amazonensis parasite cells, and then went on to test the effectiveness of the compound in treating mice with L. amazonensis infections. 

2HF stopped the proliferation of L. amazonensis parasites in both their free-living form and the form that infects human cells in both strains of L. amazonensis tested. In addition, 2HF reduced the overall number of parasites in an infected mouse, and reduced the size of lesions caused by the cutaneous form of leishmaniasis. No side effects were seen in the treated mice. “Considering that 2HF reduced the lesion size and parasite load without compromising the overall health of the infected mice, we suggest this compound as a potential candidate for leishmaniasis chemotherapy for cutaneous leishmaniasis,” the researchers say. “Studies should be conducted to determine the ideal dose and therapeutic regimen.”


Source: PLOS

07.12.2018

Read all latest stories

Related articles

Photo

News • MTX in the mix

Researchers develop novel therapy for vancomycin-resistant infections

Researchers from the US, Singapore and Geneva have developed a novel combination therapy using an anticancer agent for treating vancomycin-resistant Enterococcus faecalis (VRE).

Photo

News • Coronavirus

COVID-19: Enzyme blocks immune response to infection

Researchers from Cleveland Clinic’s Florida Research and Innovation Center (FRIC) have identified a potential new target for anti-COVID-19 therapies.

Photo

News • CRISPR

Could gold be the key to making gene therapy for HIV?

A proof-of-principle study shows that gold nanoparticles loaded with CRISPR and other gene-editing tools safely and effectively edited blood stem cells.

Related products

Subscribe to Newsletter